Citations

Clear

60 citation(s) found for "Scherber, Robyn".

Elevated Hemoglobin or Hematocrit Level
Scherber, Robyn M. , Mesa, Ruben A.

Mayo Clinic

JAMA | May 24, 2016 | Volume: 315 | Issue: 20 | Pages: 2225

10.1001/jama.2016.2435 | PMID 27218633 Get It

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group
Geyer, Holly L. , Andréasson, Björn , Dueck, Amylou C. , Scherber, Robyn M. , Martin, Kari A. , Butler, Kristina , Harrison, Claire , Radia, Deepti , Cervantes, Francisco , Kiladjian, Jean‐Jacques , Reiter, Andreas , Birgegård, Gunnar , Passamonti, Francesco , Senyak, Zhenya, Xiao, Zhijian , Samuelsson, Jan , Butler, Kristina A., Dueck, A. C. , Kosiorek, Heidi , Vannucchi, Alessandro M. , Paoli, Chiara , Mesa, Ruben A. , Kiladjian, Jean-Jacques , Passamonti, Francesco

Mayo Clinic

Cancer | April 12, 2016 | Volume: 122 | Issue: 12 | Pages: 1888-1896

10.1002/cncr.30013 | PMID 27070130 Get It

BACKGROUNDPatients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom profiles that compromise daily functioning and quality of life. Among these symptoms, sexuality‐related symptoms have emerged as particularly prominent and largely unaddressed. In the current study, the authors evaluated how sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms.METHODSA total of 1971 patients with MPN (827 with essential thrombocythemia, 682 with polycythemia vera, 456 with myelofibrosis, and 6 classified as other) were prospectively evaluated and patient responses to the Myeloproliferative Neoplasm Symptom Assessment Form (MPN‐SAF) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC‐QLQ C30) were collected, along with information regarding individual disease characteristics and laboratory data. Sexuality scores were compared with an age‐matched, healthy control population.RESULTSOverall, patients with MPN were found to have greater sexual dysfunction compared with the healthy population (MPN‐SAF score of 3.6 vs 2.0; P<.001), with 64% of patients with MPN describing some degree of sexual dysfunction and 43% experiencing severe symptoms. The presence of sexual symptoms correlated closely with all domains of patient functionality (physical, social, cognitive, emotional, and role functioning) and were associated with a reduced quality of life. Sexual problems also were found to be associated with other MPN symptoms, particularly depression and nocturnal and microvascular‐related symptoms. Sexual dysfunction was more severe in patients aged >65 years and in those with cytopenias and transfusion requirements, and those receiving certain therapies such as immunomodulators or steroids.ConclusionsThe results of the current study identify the topic of sexuality as a prominent issue for the MPN population, and this area would appear to benefit from additional investigation and management. Cancer 2016;122:1888–96. © 2016 American Cancer Society.
Comprehensively understanding fatigue in patients with myeloproliferative neoplasms
Scherber, Robyn M. , Senyak, Zhenya, Dueck, Amylou C. , Clark, Matthew M. , Boxer, Michael , Geyer, Holly L. , McCallister, Archie, Cotter, Mary, Husen, Barbara Van, Harrison, Claire , Dueck, A. C. , Kosiorek, Heidi , Mesa, Ruben A.

Mayo Clinic

Cancer | December 15, 2015 | Volume: 122 | Issue: 3 | Pages: 477-485

10.1002/cncr.29753 | PMID 26670597 Get It

BACKGROUND Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients with MPNs. METHODS A 70‐item, Internet‐based survey regarding fatigue was developed by MPN investigators and patients/advocates and hosted by the Mayo Clinic Survey Research Center. RESULTS Fatigue was found to be prevalent and severe among international survey respondents (1788 respondents). Higher body mass index ( P <.001), current use of alcohol ( P <.001), and current tobacco use ( P = .0025) were found to be significantly associated with greater fatigue. Moderate/severe fatigue was present more frequently in those individuals who did not exercise compared with those who reported exercising at least once per week ( P <.001). Medical comorbidities found to be significantly associated with greater fatigue included restless leg syndrome ( P = .006), diabetes mellitus ( P = .045), fibromyalgia ( P < 0.001), chronic fatigue syndrome ( P = .006), and chronic kidney disease ( P = .02). Current use of antidepressants ( P <.001), antihistamines ( P = .0276), antianxiety medications ( P = .0357), and prescription pain medications ( P <.001) were found to be associated with worsened fatigue. Nearly 25% of respondents scored > 2 on the Patient Health Questionnaire, indicating a high probability of depression. Higher Brief Fatigue Inventory score, Myeloproliferative Neoplasm Total Symptom Score, and individual symptom items were all associated with a higher likelihood of depressive symptoms ( P <.0001). CONCLUSIONS The management of fatigue should be multifactorial, with a comprehensive assessment and treatment plan to address all modifiable fatigue etiologies. Patients with MPNs likely have a higher prevalence of mood disturbances compared with the general population, suggesting the need to assess and intervene in this domain. Cancer 2016;122:477–485. © 2015 American Cancer Society .
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease
Geyer, Holly L. , Scherber, Robyn M. , Dueck, Amylou C. , Kiladjian, Jean‐Jacques , Xiao, Zhijian , Slot, Stefanie , Zweegman, Sonja , Sackmann, Federico, Fuentes, Ana Kerguelen, Hernández‐Maraver, Dolores , Döhner, Konstanze , Harrison, Claire , Radia, Deepti , Muxí, Pablo , Besses, Carlos , Cervantes, Francisco , Johansson, Peter , Andréasson, Björn , Rambaldi, Alessandro , Barbui, Tiziano , Bonatz, Karin, Reiter, Andreas , Boyer, Françoise, Étienne, Gabriel , Ianotto, Jean‐Christophe , Ranta, Dana, Roy, Lydia , Cahn, Jean‐Yves, Ferrari, Maria Luisa, Birgegård, Gunnar , Xu, Junqing , Zhang, Peihong , Boekhorst, Peter A.W. te , Commandeur, Suzan, Schouten, Harry C. , Pahl, Heike L. , Grießhammer, Martin , Stegelmann, Frank , Lehmann, Thomas , Senyak, Zhenya, Passamonti, Francesco , Samuelsson, Jan , Geyer, Holly, Scherber, Robyn, Hernández-Maraver, Dolores, Johansson, Peter L, Maldonado, Norman, Barosi, Giovanni , Ferrari, Maria L, Xu, Zefeng, Sun, Xiujuan, te Boekhorst, Peter A W, Schouten, Harry, Griesshammer, Martin, Dueck, A. C. , Kosiorek, Heidi , Zweegman, Sonja , Cahn, Jean‐Yves , Maldonado, Norman D. , Gale, Robert Peter , Xu, Zefeng , Zhang, Yue , Sun, Xiujuan , Vannucchi, Alessandro M. , Mesa, Ruben A. , Kiladjian, Jean-Jacques , Rambaldi, Alessandro , Ianotto, Jean-Christophe , Passamonti, Francesco

Mayo Clinic

Journal of Clinical Oncology | November 24, 2015 | Volume: 34 | Issue: 2 | Pages: 151-159

10.1200/jco.2015.62.9337 | PMID 26598745 Get It

Purpose Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and a heightened risk of life-threatening complications. Recent studies have demonstrated the effectiveness of JAK inhibitor therapy in patients with PV patients who have a history of prior hydroxyurea (HU) use (including resistance or intolerance), phlebotomy requirements, and palpable splenomegaly. We aimed to determine how these features contribute alone and in aggregate to the PV symptom burden. Patients and Methods Through prospective evaluation of 1,334 patients with PV who had characterized symptom burden, we assessed patient demographics, laboratory data, and the presence of splenomegaly by disease feature (ie, known HU use, known phlebotomy requirements, splenomegaly). Results The presence of each feature in itself is associated with a moderately high symptom burden (MPN symptom assessment form [SAF] total symptom score [TSS] range, 27.7 to 29.2) that persists independent of PV risk category. In addition, symptoms incrementally increase in severity with the addition of other features. Patients with PV who had all three features (PV-HUPS) faced the highest total score (MPN-SAF TSS, 32.5) but had similar individual symptom scores to patients with known HU use (PV-HU), known phlebotomy (PV-P), and splenomegaly (PV-S). Conclusion The results of this study suggest that patients with PV who have any one of the features in question (known HU use, known phlebotomy, or splenomegaly) have significant PV-associated symptoms. Furthermore, it demonstrates that many PV symptoms remain severe independent of the number of features present.
Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls
Anderson, Lesley , James, Glen , Duncombe, Andrew , Scherber, Robyn M. , Dueck, Amylou C. , Vocht, Frank de , Mesa, Ruben, Scherber, Robyn, Dueck, A. C. , Mesa, Ruben A. , Clarke, Mike J , McMullin, Mary Frances , Anderson, Lesley A

Mayo Clinic

American Journal of Hematology | June 25, 2015 | Volume: 90 | Issue: 10 | Pages: 864-870

10.1002/ajh.24098 | PMID 26113113 Get It

The myeloproliferative neoplasms (MPN) including polycythaemia vera (PV), essential thrombocythaemia and primary myelofibrosis (PMF) are rare diseases contributing to significant morbidity. Symptom management is a prime treatment objective but current symptom assessment tools have not been validated compared to the general population. The MPN‐symptom assessment form (MPN‐SAF), a reliable and validated clinical tool to assess MPN symptom burden, was administered to MPN patients (n = 106) and, for the first time, population controls (n = 124) as part of a UK case–control study. Mean symptom scores were compared between patients and controls adjusting for potential confounders. Mean patient scores were compared to data collected by the Mayo Clinic, USA on 1,446 international MPN patients to determine patient group representativeness. MPN patients had significantly higher mean scores than controls for 25 of the 26 symptoms measured (P < 0.05); fatigue was the most common symptom (92.4% and 78.1%, respectively). Female MPN patients suffered worse symptom burden than male patients (P < 0.001) and substantially worse burden than female controls (P < 0.001). Compared to the Mayo clinic patients, MPN‐UK patients reported similar symptom burden but lower satiety (P = 0.046). Patients with PMF reported the worst symptom burden (88.3%); significantly higher than PV patients (P < 0.001). For the first time we report quality of life was worse in MPN‐UK patients compared with controls (P < 0.001). Am. J. Hematol. 90:864–870, 2015. © 2015 Wiley Periodicals, Inc.
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Komrokji, Rami S. , Seymour, John F. , Roberts, Andrew W. , Wadleigh, Martha , To, Luen Bik, Scherber, Robyn M. , Turba, E , Dorr, Andrew, Zhu, Joy, Wang, Lixia , Granston, Tanya, Campbell, Mary S., Scherber, Robyn, Mesa, Ruben A. , Roberts, Andrew W , Komrokji, Rami S

Mayo Clinic

Blood | March 11, 2015 | Volume: 125 | Issue: 17 | Pages: 2649-2655

10.1182/blood-2013-02-484832 | PMID 25762180 Get It

Key Points Pacritinib reduced myelofibrosis-related splenomegaly and patient symptoms without causing clinically significant myelosuppression. Pacritinib had activity and was well tolerated in patients with preexisting anemia and thrombocytopenia.
Quality of life and disease understanding: impact of attending a patient‐centered cancer symposium
Padrnos, Leslie , Dueck, Amylou C. , Scherber, Robyn M. , Glassley, Pamela, Stigge, Rachel, Northfelt, Donald W. , Aguirre, Annette, Scherber, Robyn, Northfelt, Donald, Mıkhael, Joseph , Bennett, Robert M. , Mesa, Ruben A. , Dueck, A. C.

Mayo Clinic

Cancer Medicine | January 30, 2015 | Volume: 4 | Issue: 6 | Pages: 800-807

10.1002/cam4.422 | PMID 25641947 Get It

AbstractTo evaluate the impact of a patient‐centered symposium as an educational intervention on a broad population of cancer patients. We developed a comprehensive patient symposium. Through voluntary questionnaires, we studied the impact of this cancer symposium on quality of life, cancer‐specific knowledge, and symptom management among cancer patients. Symposium attendees were provided surveys prior to and 3 months following the educational intervention. Surveys included (1) EORTC‐QLQ‐C30; (2) disease understanding tool developed for this conference; (3) validated disease‐specific questionnaires. Changes over time were assessed using McNemar's tests and paired t‐tests for categorical and continuous variables, respectively. A total of 158 attendees completed the pre‐convention survey. Most respondents reported at least “quite a bit” of understanding regarding treatment options, screening modalities, symptomatology, and cancer‐related side effects. Attendees endorsed the least understanding of disease‐related stress, risk factors, fatigue management, and legal issues related to disease/treatment. At 3 months, there was improvement in understanding (12 of 14 areas of self‐reported knowledge especially regarding nutrition, and stress/fatigue management). However, no significant change was seen in QLQ‐C30 functioning, fatigue, pain, or insomnia. A patient symposium, as an educational intervention improves a solid knowledge base amongst attendees regarding their disease, increases knowledge in symptom management, but may be insufficient to impact QoL as a single intervention.
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients
Geyer, Holly L. , Scherber, Robyn M. , Dueck, Amylou C. , Kiladjian, Jean‐Jacques , Xiao, Zhijian , Slot, Stefanie , Zweegman, Sonja , Sackmann, Federico, Fuentes, Ana Kerguelen, Hernández‐Maraver, Dolores , Döhner, Konstanze , Harrison, Claire , Radia, Deepti , Muxí, Pablo , Besses, Carlos , Cervantes, Francisco , Johansson, Peter , Andréasson, Björn , Rambaldi, Alessandro , Barbui, Tiziano , Passamonti, Francesco , Samuelsson, Jan , Birgegård, Gunnar , Zweegman, Sonja , Vannucchi, Alessandro M. , Mesa, Ruben A. , Dueck, A. C. , Kiladjian, Jean-Jacques , Rambaldi, Alessandro , Passamonti, Francesco

Mayo Clinic

Blood | February 20, 2014 | Volume: 123 | Issue: 24 | Pages: 3803-3810

10.1182/blood-2013-09-527903 | PMID 24553173 Get It

Key Points Distinct clusters exist within polycythemia vera, essential thrombocythemia, and myelofibrosis. Clusters are not direct surrogates for current prognostic scores.
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Emanuel, Robyn M., Dueck, Amylou C. , Geyer, Holly L. , Kiladjian, Jean‐Jacques , Slot, Stefanie , Boekhorst, Peter A.W. te , Commandeur, Suzan, Schouten, Harry C. , Sackmann, Federico, Fuentes, Ana Kerguelen, Hernández‐Maraver, Dolores , Pahl, Heike L. , Grießhammer, Martin , Stegelmann, Frank , Doehner, Konstanze, Lehmann, Thomas , Bonatz, Karin, Reiter, Andreas , Boyer, Françoise, Étienne, Gabriel , Ianotto, Jean‐Christophe , Ranta, Dana, Roy, Lydia , Cahn, Jean‐Yves, Harrison, Claire , Radia, Deepti , Muxí, Pablo , Besses, Carlos , Cervantes, Francisco , Johansson, Peter , Barbui, Tiziano , Passamonti, Francesco , Andréasson, Björn , Ferarri, Maria L, Rambaldi, Alessandro , Samuelsson, Jan , Birgegård, Gunnar , Tefferi, Ayalew , Zweegman, Sonja , Maldonado, Norman D. , Barosi, Giovanni , Vannucchi, Alessandro M. , Mesa, Ruben A. , Dueck, A. C. , Kiladjian, Jean-Jacques , Rambaldi, Alessandro , Ianotto, Jean-Christophe , Passamonti, Francesco

Mayo Clinic

Journal of Clinical Oncology | October 16, 2012 | Volume: 30 | Issue: 33 | Pages: 4098-4103

10.1200/jco.2012.42.3863 | PMID 23071245 Get It

Purpose Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. Patients and Methods The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Results MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of 21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN disease subtypes (P < .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively. The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r = 0.59; P < .001) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) functional scales (all P < .001 and absolute r ≥ 0.50 except social functioning r = 0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF TSS had excellent internal consistency (Cronbach's α = .83). Factor analysis identified a single underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method. Conclusion The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptom study to date. This new prospective scoring method may be used to assess MPN symptom burden in both clinical practice and trial settings.
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
Scherber, Robyn M. , Dueck, Amylou C. , Johansson, Peter , Barbui, Tiziano , Passamonti, Francesco , Andréasson, Björn , Ferarri, Maria L, Rambaldi, Alessandro , Samuelsson, Jan , Birgegård, Gunnar , Tefferi, Ayalew , Harrison, Claire , Radia, Deepti , Barosi, Giovanni , Vannucchi, Alessandro M. , Mesa, Ruben A. , Dueck, A. C. , Rambaldi, Alessandro , Passamonti, Francesco

Mayo Clinic

Blood | May 2, 2011 | Volume: 118 | Issue: 2 | Pages: 401-408

10.1182/blood-2011-01-328955 | PMID 21536863 Get It

Abstract Symptomatic burden in myeloproliferative neoplasms is present in most patients and compromises quality of life. We sought to validate a broadly applicable 18-item instrument (Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF], coadministered with the Brief Fatigue Inventory) to assess symptoms of myelofibrosis, essential thrombocythemia, and polycythemia vera among prospective cohorts in the United States, Sweden, and Italy. A total of 402 MPN-SAF surveys were administered (English [25%], Italian [46%], and Swedish [28%]) in 161 patients with essential thrombocythemia, 145 patients with polycythemia vera, and 96 patients with myelofibrosis. Responses among the 3 administered languages showed great consistency after controlling for MPN subtype. Strong correlations existed between individual items and key symptomatic elements represented on both the MPN-SAF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30. Enrolling physicians' blinded opinion of patient symptoms (6 symptoms assessed) were highly correlated with corresponding patients' responses. Serial administration of the English MPN-SAF among 53 patients showed that most MPN-SAF items are well correlated (r > 0.5, P < .001) and highly reproducible (intraclass correlation coefficient > 0.7). The MPN-SAF is a comprehensive and reliable instrument that is available in multiple languages to evaluate symptoms associated with all types of MPNs in clinical trials globally.